{"id":10837,"date":"2025-05-22T16:11:03","date_gmt":"2025-05-22T20:11:03","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=10837"},"modified":"2025-05-22T16:11:03","modified_gmt":"2025-05-22T20:11:03","slug":"cellcentric-secures-120m-series-c-funding-to-advance-myeloma-drug-inobrodib","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/cellcentric-secures-120m-series-c-funding-to-advance-myeloma-drug-inobrodib\/","title":{"rendered":"CellCentric Secures $120M Series C Funding to Advance Myeloma Drug Inobrodib"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">CellCentric, a UK-based biotechnology company backed by Pfizer, has raised $120 million in Series C funding to accelerate the development of its first-in-class multiple myeloma treatment, inobrodib. The funding will support pivotal clinical trials and advance the company&#8217;s drug development pipeline for relapsed or refractory multiple myeloma.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Currently in a Phase 2a clinical trial, inobrodib\u2014an oral p300\/CBP inhibitor\u2014is being evaluated in combination with dexamethasone and Bristol Myers Squibb\u2019s Imnovid (pomalidomide). The latest readout from the American Society of Hematology (ASH) 2024 Annual Meeting showed a promising 75% overall response rate at the highest treatment level.<\/span><br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><\/p>\n<h3><b>Funding to Support Accelerated FDA Pathway<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The newly raised funds will enable a Phase 2\/3 trial targeting patients with heavily pre-treated multiple myeloma, with the goal of generating data for a potential accelerated approval application to the U.S. Food and Drug Administration (FDA).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">CellCentric also plans to use part of the funding to:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Launch a Phase 3 clinical program in mid-2026<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Initiate new studies of inobrodib in maintenance therapy settings, including combinations with bispecific antibodies<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<\/ul>\n<h3><b>Strategic Investors Fueling Growth<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The Series C round was co-led by RA Capital Management and Forbion, with additional participation from:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pfizer<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">BrightEdge, the venture capital arm of the American Cancer Society<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Avego Bioscience Capital<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">This latest raise builds on earlier investments, including a $25 million strategic investment from Pfizer in 2023 and $35 million from RA Capital in 2022.<\/span><br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\n<span style=\"font-weight: 400;\">Inobrodib works by targeting p300\/CBP, key regulators of gene expression, to reduce the activity of oncogenic drivers MYC and IRF4\u2014both known to fuel cancer progression in multiple myeloma and other malignancies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">CellCentric, originally spun out of research led by Dr. Azim Surani at the University of Cambridge, is actively expanding its U.S. presence. In April, the company opened a new office in Burlington, near Boston, to enhance its drug development capabilities and strengthen collaboration with North American partners.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CellCentric, a UK-based biotechnology company backed by Pfizer, has raised $120 million in Series C funding to accelerate the development of its first-in-class multiple myeloma treatment, inobrodib. The funding will support pivotal clinical trials and advance the company&#8217;s drug development pipeline for relapsed or refractory multiple myeloma. Currently in a Phase 2a clinical trial, inobrodib\u2014an [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10838,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-10837","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=10837"}],"version-history":[{"count":2,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10837\/revisions"}],"predecessor-version":[{"id":10840,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10837\/revisions\/10840"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/10838"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=10837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=10837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=10837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}